Evonik Rexim (Nanning) Pharmaceutical Co., Ltd. v. United States , 331 F. Supp. 3d 1415 ( 2018 )


Menu:
  •                                         Slip Op. 18- 
    UNITED STATES COURT OF INTERNATIONAL TRADE
    EVONIK REXIM (NANNING)
    PHARMACEUTICAL CO. LTD. and
    EVONIK CORPORATION,
    Plaintiffs,                               Before: Jennifer Choe-Groves, Judge
    v.                                               Court No. 17-00132
    UNITED STATES
    Defendant.
    OPINION
    [Sustaining the U.S. Department of Commerce’s remand redetermination in the administrative
    review of the antidumping duty order of glycine from the People’s Republic of China.]
    Dated: 6HSWHPEHU
    Matthew T. McGrath, Barnes, Richardson & Colburn, LLP, of Washington, D.C., for Plaintiffs
    Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. and Evonik Corporation.
    Joshua E. Kurland, Trial Attorney, Commercial Litigation Branch, Civil Division, U.S.
    Department of Justice, of Washington, D.C., for Defendant United States. Of counsel was David
    W. Campbell, Attorney, Office of Chief Counsel for Trade Enforcement and Compliance, U.S.
    Department of Commerce, of Washington, D.C.
    Choe-Groves, Judge: Plaintiffs Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. and
    Evonik Corporation (collectively, “Evonik”) challenge the final decision issued by the U.S.
    Department of Commerce (“Commerce” or “Department”) in the administrative review of the
    antidumping duty order of glycine from the People’s Republic of China for the 2013–2014
    period of review. See Glycine From the People’s Republic of China, 80 Fed. Reg. 62,027 (Dep’t
    Commerce Oct. 15, 2015) (final results of antidumping duty administrative review and partial
    rescission of antidumping duty administrative review; 2013–2014) (“Final Results”); see also
    Court No. 17-00132                                                                        Page 2
    Glycine from the People’s Republic of China: Issues and Decision Memorandum for the Final
    Results of Antidumping Duty Administrative Review; 2013–2014, A-570-836, (Oct. 5, 2015),
    available at https://enforcement.trade.gov/frn/summary/prc/2015-26270-1.pdf (last visited Sept.
    4, 2018) (“Final IDM”). The administrative review period involves entries of glycine made from
    March 1, 2013 through February 28, 2014. Final Results, 80 Fed. Reg. at 62,027.
    Evonik challenged (1) Commerce’s determination that its sales were not bona fide and
    (2) the application of the 453.79 percent China-wide entity rate during the 2013–2014
    administrative review. Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. v. United States, 41
    CIT __, __, 
    253 F. Supp. 3d 1364
    , 1370–71 (2017) (“Evonik I”), appeal docketed, No. 18-1854
    (Fed. Cir. Apr. 19, 2018). This court severed the second claim and stayed the action pending the
    final ruling in Baoding Mantong Fine Chemistry Co., Ltd. v. United States, Court No. 12-00362.
    Order, June 1, 2017, ECF No. 1. Prior decisions were issued by the court in Evonik I (sustaining
    in part and remanding in part) and Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. v. United
    States, 42 CIT __, 
    296 F. Supp. 3d 1364
    (2018) (sustaining the remand redetermination).
    Before the court are Commerce’s final results of redetermination submitted following the
    court’s grant of a voluntary remand issued on March 23, 2018. See Final Results of
    Redetermination Pursuant to Court Remand, June 5, 2018, ECF No. 9 (“Remand
    Redetermination”). For the following reasons, the court sustains the Remand Redetermination.
    BACKGROUND
    Commerce found in the underlying administrative review that Evonik’s sales of subject
    merchandise were not bona fide. See Final IDM at 24. Commerce assigned Evonik the China-
    wide entity rate of 453.79 percent, which was based on the rate assigned to Baoding Mantong
    Fine Chemistry Co., Ltd. (“Baoding”) in the final results of the antidumping administrative
    review on glycine from China for 2010–2011. Remand Redetermination at 1–2.
    Court No. 17-00132                                                                         Page 3
    In a proceeding separate from this litigation, Baoding challenged the 453.79 percent rate
    and the court issued a remand for Commerce to reconsider the rate and underlying analysis.
    Baoding Mantong Fine Chemistry Co., Ltd. v. United States, 41 CIT __, __, 
    279 F. Supp. 3d 1321
    , 1324–25 (2017) (“Baoding Mantong”). Commerce reexamined the surrogate values,
    recalculated Baoding’s weighted-average dumping margin at 0.00 percent, and invalidated the
    453.79 percent China-wide entity rate in the Second Remand Redetermination. 
    Id. The Baoding
    Mantong court found that Commerce’s decisions in the Second Remand Redetermination were
    based on substantial evidence in the record, including determinations that the ammonia
    production input was anhydrous ammonia and not aqueous ammonia, and that the anhydrous
    ammonia should be valued according to the Global Trade Atlas data for Thailand, among other
    conclusions. Id. at ___, 279 F. Supp. 3d at 1331–32. The court sustained Commerce’s Second
    Remand Redetermination as supported by the evidence in the record. 
    Id. After the
    Baoding Mantong court sustained Commerce’s Second Remand
    Redetermination reducing Baoding’s weighted-average dumping margin to 0.00 percent, this
    court granted Defendant’s Consent Motion for Voluntary Remand. Order, Mar. 23, 2018, ECF
    No. 6. In its Remand Redetermination, Commerce vacated the China-wide entity rate of 453.79
    percent and assigned an adjusted rate of 155.89 percent, which Commerce explained was the
    previous China-wide entity rate established in the underlying less-than-fair-value investigation.
    Remand Redetermination at 2, 4. Evonik did not challenge Commerce’s proposed adjusted
    China-wide entity rate of 155.89 percent. 
    Id. at 3.
    Evonik did not provide comments regarding
    the Remand Redetermination to the court.
    JURISDICTION AND STANDARD OF REVIEW
    The court has jurisdiction over Commerce’s final determination in an administrative
    review of an antidumping duty order. See 28 U.S.C. § 1581(c) (2012); 19 U.S.C.
    Court No. 17-00132                                                                           Page 4
    § 1516a(a)(2)(B)(iii). The court will uphold the Department’s determinations, findings, or
    conclusions unless unsupported by substantial evidence on the record, or otherwise not in
    accordance with law. 19 U.S.C. § 1516a(b)(1)(B)(i). When reviewing substantial evidence
    challenges to Commerce’s decisions in an administrative review, the court assesses whether the
    agency action is unreasonable given the record as a whole. See Nippon Steel Corp. v. United
    States, 
    458 F.3d 1345
    , 1350–51 (Fed. Cir. 2006).
    ANALYSIS
    The Baoding Mantong court sustained Commerce’s vacating of the previous China-wide
    entity rate of 453.79 percent based on substantial evidence considered in the Second Remand
    Redetermination. After the Baoding Mantong case invalidated the rate of 453.79 percent,
    Commerce reconsidered the appropriate rate to apply in the instant case. Commerce decided to
    apply the China-wide entity rate of 155.89 percent that had been established in the underlying
    less-than-fair-value investigation prior to the selection of the rate of 453.79 percent. The court
    concludes that Commerce’s selection of the China-wide entity rate of 155.89 percent is
    reasonable. Plaintiffs Evonik do not challenge the rate of 155.89 percent and have waived any
    objections by declining to submit comments on the Remand Redetermination to the court. The
    court sustains Commerce’s Remand Redetermination.
    Judgment will be issued accordingly.
    /s/ Jennifer Choe-Groves
    Jennifer Choe-Groves, Judge
    Dated: 6HSWHPEHU
    New York, New York
    

Document Info

Docket Number: 17-00132

Citation Numbers: 2018 CIT 112, 331 F. Supp. 3d 1415

Judges: Choe-Groves

Filed Date: 9/7/2018

Precedential Status: Precedential

Modified Date: 9/7/2018